Stock Market News
Scancell Holdings granted European patent for Moditope
AIM-quoted immunotherapies developer Scancell Holdings has been granted a European patent for its Moditope platform by the European Patent Office.
Coming into effect on 13 June, the patent will provide Scancell "broad protection" for its pipeline of Moditope vaccines, including any citrullinated epitopes for the treatment of cancer, including in all major European territories.
Scancell has filed similar patents in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.
Moditope, a "new class" of potent and selective immunotherapy agents, stimulates the production of killer CD4 T cells which overcomes immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Lindy Durrant, chief scientific officer of Scancell, said, "This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins."
"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma," Durrant added.
As of 1020 BST, Scancell shares had collected 2.41% to 14.85p.
Coming into effect on 13 June, the patent will provide Scancell "broad protection" for its pipeline of Moditope vaccines, including any citrullinated epitopes for the treatment of cancer, including in all major European territories.
Scancell has filed similar patents in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.
Moditope, a "new class" of potent and selective immunotherapy agents, stimulates the production of killer CD4 T cells which overcomes immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Lindy Durrant, chief scientific officer of Scancell, said, "This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins."
"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma," Durrant added.
As of 1020 BST, Scancell shares had collected 2.41% to 14.85p.
Related share prices |
---|
Scancell Holdings (SCLP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price